Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$26.24 - $39.63 $219,733 - $331,861
-8,374 Reduced 6.88%
113,294 $4.46 Million
Q1 2023

May 15, 2023

BUY
$18.67 - $24.56 $1.3 Million - $1.71 Million
69,478 Added 133.13%
121,668 $2.96 Million
Q4 2022

Feb 14, 2023

BUY
$17.24 - $23.95 $264,392 - $367,297
15,336 Added 41.61%
52,190 $1.12 Million
Q3 2022

Nov 14, 2022

BUY
$9.4 - $18.59 $23,020 - $45,526
2,449 Added 7.12%
36,854 $661,000
Q2 2022

Aug 22, 2022

BUY
$9.12 - $18.9 $41,869 - $86,769
4,591 Added 15.4%
34,405 $331,000
Q1 2022

May 16, 2022

BUY
$12.15 - $16.83 $20,849 - $28,880
1,716 Added 6.11%
29,814 $502,000
Q4 2021

Feb 14, 2022

BUY
$13.83 - $18.78 $26,097 - $35,437
1,887 Added 7.2%
28,098 $470,000
Q3 2021

Nov 15, 2021

BUY
$7.07 - $17.5 $100,804 - $249,515
14,258 Added 119.28%
26,211 $426,000
Q2 2021

Aug 12, 2021

BUY
$5.69 - $7.17 $5,069 - $6,388
891 Added 8.05%
11,953 $75,000
Q4 2020

Feb 12, 2021

BUY
$5.65 - $7.66 $23,701 - $32,133
4,195 Added 61.09%
11,062 $76,000
Q3 2020

Nov 13, 2020

BUY
$4.01 - $6.29 $4,487 - $7,038
1,119 Added 19.47%
6,867 $39,000
Q2 2020

Aug 14, 2020

BUY
$3.06 - $6.6 $17,588 - $37,936
5,748 New
5,748 $29,000

Others Institutions Holding ISEE

About IVERIC bio, Inc.


  • Ticker ISEE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,078,000
  • Description
  • IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...
More about ISEE
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.